| Year |
Citation |
Score |
| 2024 |
Magbanua MJM, Ahmed Z, Sayaman RW, Brown Swigart L, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Perlmutter J, Pohlmann P, Symmans WF, Yee D, Hylton NM, Esserman LJ, et al. Cell-free DNA concentration as a biomarker of response and recurrence in HER2-negative breast cancer receiving neoadjuvant chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 38470545 DOI: 10.1158/1078-0432.CCR-23-2928 |
0.326 |
|
| 2023 |
Kyalwazi B, Yau C, Campbell MJ, Yoshimatsu TF, Chien AJ, Wallace AM, Forero-Torres A, Pusztai L, Ellis ED, Albain KS, Blaes AH, Haley BB, Boughey JC, Elias AD, Clark AS, ... ... Yee D, et al. Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer. Jama Network Open. 6: e2349646. PMID 38153734 DOI: 10.1001/jamanetworkopen.2023.49646 |
0.354 |
|
| 2023 |
Albain KS, Yau C, Petricoin EF, Wolf DM, Lang JE, Chien AJ, Haddad T, Forero-Torres A, Wallace AM, Kaplan H, Pusztai L, Euhus D, Nanda R, Elias AD, Clark AS, ... ... Yee D, et al. Neoadjuvant trebananib plus paclitaxel-based chemotherapy for stage II/III breast cancer in the adaptively randomized I-SPY2 trial - Efficacy and biomarker discovery. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 38109213 DOI: 10.1158/1078-0432.CCR-22-2256 |
0.396 |
|
| 2023 |
Gallagher RI, Wulfkuhle J, Wolf DM, Brown-Swigart L, Yau C, O'Grady N, Basu A, Lu R, Campbell MJ, Magbanua MJ, Coppé JP, Asare SM, Sit L, Matthews JB, Perlmutter J, ... ... Yee D, et al. Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial. Cell Reports. Medicine. 101312. PMID 38086377 DOI: 10.1016/j.xcrm.2023.101312 |
0.368 |
|
| 2023 |
Monteiro M, Zhang X, Yee D. Insulin promotes growth in breast cancer cells through the type I IGF receptor in insulin receptor deficient cells. Experimental Cell Research. 434: 113862. PMID 38036052 DOI: 10.1016/j.yexcr.2023.113862 |
0.561 |
|
| 2023 |
Rajoria B, Zhang X, Yee D. IGF-1 Stimulates Glycolytic ATP Production in MCF-7L Cells. International Journal of Molecular Sciences. 24. PMID 37373357 DOI: 10.3390/ijms241210209 |
0.435 |
|
| 2023 |
Tarullo SE, He Y, Daughters C, Knutson TP, Henzler CM, Price MA, Shanley R, Witschen P, Tolg C, Kaspar RE, Hallstrom C, Gittsovich L, Sulciner ML, Zhang X, Forster CL, ... ... Yee D, et al. Receptor for hyaluronan-mediated motility (RHAMM) defines an invasive niche associated with tumor progression and predicts poor outcomes in breast cancer patients. The Journal of Pathology. PMID 37186300 DOI: 10.1002/path.6082 |
0.413 |
|
| 2023 |
Magbanua MJM, Brown Swigart L, Ahmed Z, Sayaman RW, Renner D, Kalashnikova E, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Asare S, Liu MC, Albain K, Chien AJ, ... ... Yee D, et al. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell. PMID 37146605 DOI: 10.1016/j.ccell.2023.04.008 |
0.404 |
|
| 2023 |
Zhang X, Varma S, Yee D. Suppression of Insulin Receptor Substrate 1 Inhibits Breast Cancer Growth In Vitro and in Female Athymic Mice. Endocrinology. 164. PMID 36610717 DOI: 10.1210/endocr/bqac214 |
0.549 |
|
| 2022 |
Lang JE, Forero-Torres A, Yee D, Yau C, Wolf D, Park J, Parker BA, Chien AJ, Wallace AM, Murthy R, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, et al. Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer. Npj Breast Cancer. 8: 128. PMID 36456573 DOI: 10.1038/s41523-022-00493-z |
0.409 |
|
| 2022 |
Vijayakumar J, Haddad T, Gupta K, Sauers J, Yee D. An open label phase II study of safety and clinical activity of naltrexone for treatment of hormone refractory metastatic breast cancer. Investigational New Drugs. PMID 36441436 DOI: 10.1007/s10637-022-01317-4 |
0.374 |
|
| 2022 |
Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher IR, Lee PRE, Zhu Z, Magbanua MJ, Sayaman R, O'Grady N, Basu A, Delson A, Coppé JP, Lu R, Braun J, ... ... Yee D, et al. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell. PMID 35623341 DOI: 10.1016/j.ccell.2022.05.005 |
0.351 |
|
| 2022 |
Qin X, Huckfeldt P, Abraham J, Yee D, Virnig BA. Hormonal Therapy Drug Switching, Out-of-Pocket Costs, and Adherence among Older Women with Breast Cancer. Journal of the National Cancer Institute. PMID 35333338 DOI: 10.1093/jnci/djac062 |
0.328 |
|
| 2021 |
Clark AS, Yau C, Wolf DM, Petricoin EF, van 't Veer LJ, Yee D, Moulder SL, Wallace AM, Chien AJ, Isaacs C, Boughey JC, Albain KS, Kemmer K, Haley BB, Han HS, et al. Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2 breast cancer in the adaptively randomized I-SPY2 trial. Nature Communications. 12: 6428. PMID 34741023 DOI: 10.1038/s41467-021-26019-y |
0.34 |
|
| 2021 |
Yee D, Isaacs C, Wolf DM, Yau C, Haluska P, Giridhar KV, Forero-Torres A, Jo Chien A, Wallace AM, Pusztai L, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, et al. Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. Npj Breast Cancer. 7: 131. PMID 34611148 DOI: 10.1038/s41523-021-00337-2 |
0.452 |
|
| 2021 |
Symmans WF, Yau C, Chen YY, Balassanian R, Klein ME, Pusztai L, Nanda R, Parker BA, Datnow B, Krings G, Wei S, Feldman MD, Duan X, Chen B, Sattar H, ... ... Yee D, et al. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial. Jama Oncology. PMID 34529000 DOI: 10.1001/jamaoncol.2021.3690 |
0.361 |
|
| 2021 |
Moy B, Rumble RB, Come SE, Davidson NE, Di Leo A, Gralow JR, Hortobagyi GN, Yee D, Smith IE, Chavez-MacGregor M, Nanda R, McArthur HL, Spring L, Reeder-Hayes KE, Ruddy KJ, et al. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2101374. PMID 34324366 DOI: 10.1200/JCO.21.01374 |
0.435 |
|
| 2021 |
Mathur T, Yee D. The emerging role of the fetal insulin receptor (IR-A) in hormone-refractory breast cancer. Endocrinology. PMID 34304271 DOI: 10.1210/endocr/bqab147 |
0.488 |
|
| 2021 |
Kamaraju S, Fowler AM, Weil E, Wisinski KB, Truong TH, Lehr M, Chaudhary LN, Cheng YC, Chitambar C, Rui H, Yee D, Lange C. Leveraging Antiprogestins in the Treatment of Metastatic Breast Cancer. Endocrinology. PMID 33735382 DOI: 10.1210/endocr/bqab060 |
0.397 |
|
| 2021 |
Potter DA, Herrera-Ponzanelli CA, Hinojosa D, Castillo R, Hernandez-Cruz I, Arrieta VA, Franklin MJ, Yee D. Recent advances in neoadjuvant therapy for breast cancer. Faculty Reviews. 10: 2. PMID 33659921 DOI: 10.12703/r/10-2 |
0.362 |
|
| 2021 |
Cao J, Yee D. Disrupting Insulin and IGF Receptor Function in Cancer. International Journal of Molecular Sciences. 22. PMID 33429867 DOI: 10.3390/ijms22020555 |
0.495 |
|
| 2021 |
Wang H, Zhang S, Yee D, Basu S, Beckwith H, Potter D, Blaes A. Impact of body mass index on pathological complete response following neoadjuvant chemotherapy in operable breast cancer: a meta-analysis. Breast Cancer (Tokyo, Japan). PMID 33387284 DOI: 10.1007/s12282-020-01194-w |
0.309 |
|
| 2020 |
Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, et al. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. Jama Oncology. PMID 32701140 DOI: 10.1001/Jamaoncol.2020.2535 |
0.337 |
|
| 2020 |
Fettig LM, Yee D. Advances in insulin-like growth factor biology and -directed cancer therapeutics. Advances in Cancer Research. 147: 229-257. PMID 32593402 DOI: 10.1016/Bs.Acr.2020.04.005 |
0.541 |
|
| 2020 |
Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, ... ... Yee D, et al. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. Jama Oncology. PMID 32053137 DOI: 10.1001/Jamaoncol.2019.6650 |
0.442 |
|
| 2020 |
Kulkarni A, Jewett P, Blaes AH, Yee D. Impact of antibiotics on residual cancer burden and pathologic response rates during neoadjuvant pembrolizumab in breast cancer (BC). Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E12622 |
0.443 |
|
| 2020 |
Onishi N, Li W, Newitt DC, Harnish R, Gibbs J, Jones EF, Nguyen A, Wilmes L, Joe BN, Campbell MJ, Basu A, Veer LJv, DiMichele A, Yee D, Berry DA, et al. Abstract PD9-05: Lack of background parenchymal enhancement suppression in breast MRI during neoadjuvant chemotherapy may be associated with inferior treatment response in hormone receptor positive breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-Pd9-05 |
0.466 |
|
| 2020 |
Li W, Onishi N, Newitt DC, Gibbs J, Wilmes LJ, Jones EF, Joe BN, Sit LS, Yau C, Chien AJ, Price E, Albain KS, Kuritza T, Morley K, Boughey JC, ... ... Yee D, et al. Abstract PD9-04: Breast cancer subtype specific association of pCR with MRI assessed tumor volume progression during NAC in the I-SPY 2 trial Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Pd9-04 |
0.352 |
|
| 2020 |
Li W, Onishi N, Newitt DC, Harnish R, Jones EF, Wilmes LJ, Gibbs J, Price E, Joe BN, Chien AJ, Berry DA, Boughey JC, Albain KS, Clark AS, Edmiston KK, ... ... Yee D, et al. Abstract P6-02-01: The effect of background parenchymal enhancement on the predictive performance of functional tumor volume measured in MRI Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P6-02-01 |
0.364 |
|
| 2020 |
Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Asare SM, Hirst GL, Sit L, Perlmutter J, Liu M, Park J, DeMichele A, Yee D, Berry D, Esserman L, Petricoin E, et al. Abstract P4-10-02: HER2 signaling, ER, and proliferation biomarkers predict response to multiple HER2-targeted agents/combinations plus standard neoadjuvant therapy in the I-SPY 2 trial Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P4-10-02 |
0.358 |
|
| 2020 |
Yee D, Oliveira M, Iwata H, Gonçalves A, García-Corbacho J, Sablin MP, Prat A, Hardebeck MC, Puig M, Huang DC, Hsu M, LoRusso P. Abstract P3-11-05: A phase Ib multi-cohort study of xentuzumab and abemaciclib in patients (pts) with solid tumors and breast cancer (BC) - Initial report of four dose-finding cohorts Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P3-11-05 |
0.423 |
|
| 2020 |
Helsten TL, Lo SS, Yau C, Kalinsky K, Elias AD, Wallace AM, Chien AJ, Lu J, Lang JE, Albain KS, Stringer-Reasor E, Clark AS, Boughey JC, Ellis ED, Yee D, et al. Abstract P3-11-02: Evaluation of patritumab/paclitaxel/trastuzumab over standard paclitaxel/trastuzumab in early stage, high-risk HER2 positive breast cancer: Results from the neoadjuvant I-SPY 2 trial Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P3-11-02 |
0.425 |
|
| 2020 |
Zhang X, Yee D. Abstract P3-10-09: Gene deletion of IRS1 inhibited IGF-I, insulin and estradiol stimulated MCF-7L breast cancer cell growth Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P3-10-09 |
0.628 |
|
| 2020 |
Liu MC, Robinson PA, Yau C, Wallace AM, Chien AJ, Stringer-Reasor E, Nanda R, Yee D, Albain KS, Boughey JC, Han HS, Elias AD, Kalinsky K, Clark AS, Kemmer K, et al. Abstract P3-09-02: Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P3-09-02 |
0.429 |
|
| 2020 |
Wang H, Zhang S, Yee D, Beckwith H, Potter D, Blaes A. Abstract P3-08-39: Pathological complete response following neoadjuvant chemotherapy in operable breast cancer patients: Is obesity a predictive factor? Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P3-08-39 |
0.453 |
|
| 2020 |
Yau C, DeMichele A, Symmans WF, Pusztai L, Yee D, Clark AS, Hatzis C, Matthews JB, Carter J, Chen Y, Cole K, Khazai L, Klein M, Kokh D, Krings G, et al. Abstract P2-20-02: Site of recurrence after neoadjuvant therapy: Clues to biology and impact on endpoints Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P2-20-02 |
0.327 |
|
| 2020 |
Fettig LM, Zhang X, LaPara K, Murikipudi S, Delpero AR, Lancaster TM, Zion TC, Yee D. Abstract P1-21-05: A novel long-acting insulin for cancer therapy reduces xenograft tumor growth Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P1-21-05 |
0.638 |
|
| 2020 |
LoRusso P, García-Corbacho J, Braiteh FS, Gonçalves A, Ricci F, Iwata H, Capelán M, Sablin MP, Prat A, Hardebeck MC, Puig M, Huang DC, Hsu M, Yee D. Abstract CT165: An open label, multi-cohort, phase Ib study of xentuzumab and abemaciclib: Preliminary results from the advanced non-small cell lung cancer (NSCLC) cohort Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Ct165 |
0.389 |
|
| 2020 |
Pusztai L, Han HS, Yau C, Wolf D, Wallace AM, Shatsky R, Helsten T, Boughey JC, Haddad T, Stringer-Reasor E, Falkson C, Chien AJ, Mukhtar R, Elias A, Virginia B, ... ... Yee D, et al. Abstract CT011: Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Ct011 |
0.465 |
|
| 2019 |
Wang H, Yee D. I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer. Current Breast Cancer Reports. 11: 303-310. PMID 33312344 DOI: 10.1007/S12609-019-00334-2 |
0.369 |
|
| 2019 |
Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, Wallace AM, Schwab R, Helsten T, Forero-Torres A, Stringer-Reasor E, Ellis ED, Kaplan HG, Nanda R, Jaskowiak N, ... ... Yee D, et al. MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1901027. PMID 32031889 DOI: 10.1200/Jco.19.01027 |
0.561 |
|
| 2019 |
Samavat H, Wu AH, Ursin G, Torkelson CJ, Wang R, Yu MC, Yee D, Kurzer MS, Yuan JM. Green Tea Catechin Extract Supplementation Does Not Influence Circulating Sex Hormones and Insulin-Like Growth Factor Axis Proteins in a Randomized Controlled Trial of Postmenopausal Women at High Risk of Breast Cancer. The Journal of Nutrition. PMID 30926986 DOI: 10.1093/Jn/Nxy316 |
0.492 |
|
| 2019 |
Ekyalongo R, Abdelwahab R, Holtz A, Sabet A, Yee D. Abstract P5-03-05: Model of acquired resistance to the tyrphostin NT157 in hormone receptor-positive breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-P5-03-05 |
0.481 |
|
| 2019 |
Hylton N, Symmans W, Yau C, Li W, Hatzis C, Isaacs C, Albain K, Chen Y, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, ... ... Yee D, et al. Abstract P2-07-03: Refining neoadjuvant predictors of three year distant metastasis free survival: Integrating volume change as measured by MRI with residual cancer burden Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-P2-07-03 |
0.31 |
|
| 2019 |
LaPara K, Chan J, Zdechlik A, Ljunggren K, Schmidt D, Hackel B, Yee D. Abstract P1-05-03: Isoform specific targeting of insulin receptor Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-P1-05-03 |
0.393 |
|
| 2019 |
Schwab R, Clark AS, Yau C, Hylton N, Li W, Wolfe D, Chien AJ, Wallace AM, Forero-Torres A, Stringer-Reasor E, Nanda R, Jaskowiak N, Boughey J, Haddad T, Han HS, ... ... Yee D, et al. Abstract CT136: Evaluation of talazoparib in combination with irinotecan in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct136 |
0.411 |
|
| 2019 |
Campbell MJ, Yau C, Bolen J, Vandenberg S, Hoyt C, Brown-Swigart L, Hirst G, Nanda R, Liu M, Asare S, van'tVeer L, Yee D, DeMichele A, Berry D, Esserman L, et al. Abstract CT003: Analysis of immune cell infiltrates as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY 2 TRIAL Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct003 |
0.354 |
|
| 2019 |
Wolf DM, Yau C, Wulfkuhle J, Petricoin E, Brown-Swigart L, Hirst G, Asare S, Yee D, DeMichele A, Rugo H, Olopade O, Nanda R, Liu M, Esserman L, Veer Lvt. Abstract 2679: Integration of DNA repair deficiency and immune biomarkers to predict which early-stage triple-negative breast cancer patients are likely to respond to platinum-containing regimens vs. immunotherapy: The neoadjuvant I-SPY 2 trial Cancer Research. 79: 2679-2679. DOI: 10.1158/1538-7445.Am2019-2679 |
0.337 |
|
| 2018 |
Wulfkuhle JD, Yau C, Wolf DM, Vis DJ, Gallagher RI, Brown-Swigart L, Hirst G, Voest EE, DeMichele A, Hylton N, Symmans F, Yee D, Esserman L, Berry D, Liu M, et al. Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL. Jco Precision Oncology. 2. PMID 32914002 DOI: 10.1200/PO.18.00024 |
0.374 |
|
| 2018 |
Ungerleider NA, Rao SG, Shahbandi A, Yee D, Niu T, Frey WD, Jackson JG. Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment. Breast Cancer Research : Bcr. 20: 115. PMID 30285883 DOI: 10.1186/S13058-018-1044-5 |
0.408 |
|
| 2018 |
Yang Y, Chan JY, Temiz NA, Yee D. Insulin Receptor Substrate Suppression by the Tyrphostin NT157 Inhibits Responses to Insulin-Like Growth Factor-I and Insulin in Breast Cancer Cells. Hormones & Cancer. PMID 30229539 DOI: 10.1007/S12672-018-0343-8 |
0.633 |
|
| 2018 |
Yee D. Anti-Insulin-like Growth Factor Therapy in Breast Cancer. Journal of Molecular Endocrinology. PMID 29378771 DOI: 10.1530/Jme-17-0261 |
0.577 |
|
| 2018 |
Blaes AH, Beckwith HC, Hebbel RP, Solovey AS, Potter D, Yee D, Petersen A, Vogel RI, Luepker RV, Duprez D. Longitudinal follow-up of endothelial function in breast cancer survivors on aromatase inhibitors (AIs). Journal of Clinical Oncology. 36: e12525-e12525. DOI: 10.1200/Jco.2018.36.15_Suppl.E12525 |
0.358 |
|
| 2018 |
Symmans WF, Yau C, Chen Y, Datnow B, Wei S, Feldman MD, Ritter J, Duan X, Chen B, Tickman R, Sattar H, Magliocco AM, Kallakury B, Troxell M, Asare S, ... ... Yee D, et al. Residual cancer burden (RCB) as prognostic in the I-SPY 2 TRIAL. Journal of Clinical Oncology. 36: 520-520. DOI: 10.1200/Jco.2018.36.15_Suppl.520 |
0.414 |
|
| 2018 |
Yee D, Sablin M, Iwata H, Johnston E, Bogenrieder T, Serra J, Hua H, Russo PL, Prat A. Abstract OT3-06-02: A phase Ib trial of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumors, including hormone receptor-positive, HER2-negative breast cancer (plus endocrine therapy) Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Ot3-06-02 |
0.464 |
|
| 2017 |
DeMichele A, Yee D, Esserman L. Mechanisms of Resistance to Neoadjuvant Chemotherapy in Breast Cancer. The New England Journal of Medicine. 377: 2287-2289. PMID 29211674 DOI: 10.1056/Nejmcibr1711545 |
0.486 |
|
| 2017 |
Ekyalongo RC, Yee D. Revisiting the IGF-1R as a breast cancer target. Npj Precision Oncology. 1. PMID 29152592 DOI: 10.1038/s41698-017-0017-y |
0.414 |
|
| 2017 |
Lee H, Ghebre R, Le C, Jang YJ, Sharratt M, Yee D. Mobile Phone Multilevel and Multimedia Messaging Intervention for Breast Cancer Screening: Pilot Randomized Controlled Trial. Jmir Mhealth and Uhealth. 5: e154. PMID 29113961 DOI: 10.2196/Mhealth.7091 |
0.387 |
|
| 2017 |
Samavat H, Ursin G, Emory TH, Lee E, Wang R, Torkelson CJ, Dostal AM, Swenson K, Le CT, Yang CS, Yu MC, Yee D, Wu AH, Yuan JM, Kurzer MS. A Randomized Controlled Trial of Green Tea Extract Supplementation and Mammographic Density in Postmenopausal Women at Increased Risk of Breast Cancer. Cancer Prevention Research (Philadelphia, Pa.). PMID 28904061 DOI: 10.1158/1940-6207.Capr-17-0187 |
0.324 |
|
| 2017 |
Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, ... ... Yee D, et al. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. Breast Cancer Research : Bcr. 19: 107. PMID 28893315 DOI: 10.1186/S13058-017-0896-4 |
0.399 |
|
| 2017 |
Blaes A, Beckwith H, Florea N, Hebbel R, Solovey A, Potter D, Yee D, Vogel R, Luepker R, Duprez D. Vascular function in breast cancer survivors on aromatase inhibitors: a pilot study. Breast Cancer Research and Treatment. PMID 28801846 DOI: 10.1007/S10549-017-4447-6 |
0.47 |
|
| 2017 |
Fagan DH, Fettig LM, Avdulov S, Beckwith H, Peterson MS, Ho YY, Wang F, Polunovsky VA, Yee D. Acquired Tamoxifen Resistance in MCF-7 Breast Cancer Cells Requires Hyperactivation of eIF4F-Mediated Translation. Hormones & Cancer. PMID 28577281 DOI: 10.1007/S12672-017-0296-3 |
0.775 |
|
| 2017 |
Chan JY, Hackel BJ, Yee D. Targeting insulin receptor in breast cancer using small engineered protein scaffolds. Molecular Cancer Therapeutics. PMID 28468775 DOI: 10.1158/1535-7163.Mct-16-0685 |
0.571 |
|
| 2017 |
Nanda R, Liu MC, Yau C, Asare S, Hylton N, Veer LV, Perlmutter J, Wallace AM, Chien AJ, Forero-Torres A, Ellis E, Han H, Sanders Clark A, Albain KS, Caroline Boughey J, ... ... Yee D, et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2. Journal of Clinical Oncology. 35: 506-506. DOI: 10.1200/Jco.2017.35.15_Suppl.506 |
0.336 |
|
| 2017 |
Yee D, Prat A, Sablin MP, Iwata H, Johnston EL, Bogenrieder T, Serra J, Hua H, LoRusso P. 235TiPA Phase Ib trial of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumours, hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer (BC; +/-endocrine therapy), or non-small-cell lung cancer (NSCLC) Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx656.001 |
0.491 |
|
| 2016 |
Bolan PJ, Kim E, Herman BA, Newstead GM, Rosen MA, Schnall MD, Pisano ED, Weatherall PT, Morris EA, Lehman CD, Garwood M, Nelson MT, Yee D, Polin SM, Esserman LJ, et al. MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial. Journal of Magnetic Resonance Imaging : Jmri. PMID 27981651 DOI: 10.1002/Jmri.25560 |
0.431 |
|
| 2016 |
Law EK, Sieuwerts AM, LaPara K, Leonard B, Starrett GJ, Molan AM, Temiz NA, Vogel RI, Meijer-van Gelder ME, Sweep FC, Span PN, Foekens JA, Martens JW, Yee D, Harris RS. The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer. Science Advances. 2: e1601737. PMID 27730215 DOI: 10.1126/Sciadv.1601737 |
0.454 |
|
| 2016 |
Kruziki MA, Case BA, Chan JY, Zudock EJ, Woldring DR, Yee D, Hackel BJ. A 64Cu-labeled Gp2 Domain for PET Imaging of Epidermal Growth Factor Receptor. Molecular Pharmaceutics. PMID 27696863 DOI: 10.1021/Acs.Molpharmaceut.6B00538 |
0.309 |
|
| 2016 |
Zelenko Z, Gallagher EJ, Antoniou IM, Sachdev D, Nayak A, Yee D, LeRoith D. EMT Reversal in human cancer cells after IR knockdown in hyperinsulinemic mice. Endocrine-Related Cancer. PMID 27435064 DOI: 10.1530/Erc-16-0142 |
0.51 |
|
| 2016 |
Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, et al. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. The New England Journal of Medicine. 375: 23-34. PMID 27406347 DOI: 10.1056/Nejmoa1513749 |
0.49 |
|
| 2016 |
Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, et al. Adaptive Randomization of Neratinib in Early Breast Cancer. The New England Journal of Medicine. 375: 11-22. PMID 27406346 DOI: 10.1056/Nejmoa1513750 |
0.477 |
|
| 2016 |
Becker MA, Ibrahim YH, Oh AS, Fagan DH, Byron SA, Sarver AL, Lee AV, Shaw LM, Fan C, Perou CM, Yee D. Insulin Receptor Substrate Adaptor Proteins Mediate Prognostic Gene Expression Profiles in Breast Cancer. Plos One. 11: e0150564. PMID 26991655 DOI: 10.1371/Journal.Pone.0150564 |
0.836 |
|
| 2016 |
Ochnik AM, Peterson MS, Avdulov SV, Oh AS, Bitterman PB, Yee D. Amplified in Breast Cancer Regulates Transcription and Translation in Breast Cancer Cells. Neoplasia (New York, N.Y.). 18: 100-10. PMID 26936396 DOI: 10.1016/J.Neo.2016.01.001 |
0.552 |
|
| 2016 |
Chan JY, LaPara K, Yee D. Disruption of insulin receptor function inhibits proliferation in endocrine-resistant breast cancer cells. Oncogene. PMID 26876199 DOI: 10.1038/Onc.2015.488 |
0.626 |
|
| 2016 |
DeMichele A, Yee D, Paoloni M, Berry D, Esserman LJ. Neoadjuvant as Future for Drug Development in Breast Cancer--Response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 22: 269. PMID 26728411 DOI: 10.1158/1078-0432.Ccr-15-1643 |
0.394 |
|
| 2016 |
P. Schwerkoske J, Yee D. New Ways to Improve Breast Cancer Therapy Targeting Specific Molecular Pathways Current Cancer Therapy Reviews. 11: 222-259. DOI: 10.2174/1573394712666151215220005 |
0.469 |
|
| 2016 |
Harris R, Law E, Sieuwerts A, LaPara K, Leonard B, Starrett G, Temiz N, Sweep F, Span P, Foekens J, Martens J, Yee D. Abstract S4-07: Tamoxifen resistance driven by the DNA cytosine deaminase APOBEC3B in recurrent estrogen receptor positive breast cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-S4-07 |
0.531 |
|
| 2016 |
Buxton M, DeMichele AM, Chia S, Veer Lv, Chien J, Wallace A, Kaplan H, Lang J, Yee D, Isaacs C, Moulder S, Albain K, Boughey J, Kemmer K, Haley B, et al. Abstract CT106: Efficacy of pertuzumab/trastuzumab/paclitaxel over standard trastuzumab/paclitaxel therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Ct106 |
0.425 |
|
| 2016 |
DeMichele AM, Moulder S, Buxton M, Yee D, Wallace A, Chien J, Isaacs C, Albain K, Boughey J, Kemmer K, Haley B, Lang J, Kaplan H, Minton S, Forero A, et al. Abstract CT042: Efficacy of T-DM1+pertuzumab over standard therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Ct042 |
0.392 |
|
| 2016 |
Zhang X, Varma S, Yee D. Abstract 4406: Inducible knockdown of insulin receptor substrate I desensitizes ER alpha response to both agonist (estradiol) and antagonist (fulvestrant) in MCF-7L breast cancer cells Cancer Research. 76: 4406-4406. DOI: 10.1158/1538-7445.Am2016-4406 |
0.579 |
|
| 2016 |
LaPara KS, Law E, Harris R, Yee D. Abstract 295: The cytosine deaminase APOBEC3B affects responses to therapy in estrogen receptor positive breast cancer cells Cancer Research. 76: 295-295. DOI: 10.1158/1538-7445.Am2016-295 |
0.54 |
|
| 2016 |
Chan JY, LaPara K, Yee D. Disruption of insulin receptor function inhibits proliferation in endocrine-resistant breast cancer cells Oncogene. DOI: 10.1038/onc.2015.488 |
0.493 |
|
| 2015 |
Blaes AH, Rehman A, Vock DM, Luo X, Menge M, Yee D, Missov E, Duprez D. Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy. Vascular Health and Risk Management. 11: 591-4. PMID 26648730 DOI: 10.2147/Vhrm.S89842 |
0.341 |
|
| 2015 |
Walter W, Thomalla J, Bruhn J, Fagan DH, Zehowski C, Yee D, Skildum A. Altered regulation of PDK4 expression promotes antiestrogen resistance in human breast cancer cells. Springerplus. 4: 689. PMID 26576332 DOI: 10.1186/S40064-015-1444-2 |
0.769 |
|
| 2015 |
Beckwith H, Yee D. Minireview: Were the IGF Signaling Inhibitors All Bad? Molecular Endocrinology (Baltimore, Md.). 29: 1549-57. PMID 26366975 DOI: 10.1210/Me.2015-1157 |
0.444 |
|
| 2015 |
Samavat H, Dostal AM, Wang R, Bedell S, Emory TH, Ursin G, Torkelson CJ, Gross MD, Le CT, Yu MC, Yang CS, Yee D, Wu AH, Yuan JM, Kurzer MS. The Minnesota Green Tea Trial (MGTT), a randomized controlled trial of the efficacy of green tea extract on biomarkers of breast cancer risk: study rationale, design, methods, and participant characteristics. Cancer Causes & Control : Ccc. PMID 26206423 DOI: 10.1007/S10552-015-0632-2 |
0.375 |
|
| 2015 |
Huang X, Park H, Greene J, Pao J, Mulvey E, Zhou SX, Albert CM, Moy F, Sachdev D, Yee D, Rader C, Hamby CV, Loeb DM, Cairo MS, Zhou X. IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas. Plos One. 10: e0133152. PMID 26173023 DOI: 10.1371/Journal.Pone.0133152 |
0.385 |
|
| 2015 |
DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, et al. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2911-5. PMID 25712686 DOI: 10.1158/1078-0432.Ccr-14-1760 |
0.448 |
|
| 2015 |
Yee D. CCR 20th Anniversary commentary: stayin' alive-antiapoptotic proteins and breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 665-6. PMID 25691771 DOI: 10.1158/1078-0432.Ccr-14-2548 |
0.484 |
|
| 2015 |
Blaes A, Duprez D, Defor T, Shanley R, Beckwith H, Haddad T, Potter D, Yee D, Sanghavi K, Jacobson P. Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment. Springerplus. 4: 32. PMID 25646154 DOI: 10.1186/S40064-015-0802-4 |
0.359 |
|
| 2015 |
Hui SK, Arentsen L, Wilcox A, Shanley R, Yee D, Ghebre R. Spatial and temporal fracture pattern in breast and gynecologic cancer survivors. Journal of Cancer. 6: 66-9. PMID 25553090 DOI: 10.7150/Jca.10288 |
0.328 |
|
| 2015 |
Hui SK, Arentsen L, Sueblinvong T, Brown K, Bolan P, Ghebre RG, Downs L, Shanley R, Hansen KE, Minenko AG, Takhashi Y, Yagi M, Zhang Y, Geller M, Reynolds M, ... ... Yee D, et al. A phase I feasibility study of multi-modality imaging assessing rapid expansion of marrow fat and decreased bone mineral density in cancer patients. Bone. 73: 90-7. PMID 25536285 DOI: 10.1016/J.Bone.2014.12.014 |
0.339 |
|
| 2015 |
Avdulov S, Herrera J, Smith K, Peterson M, Gomez-Garcia JR, Beadnell TC, Schwertfeger KL, Benyumov AO, Manivel JC, Li S, Bielinsky AK, Yee D, Bitterman PB, Polunovsky VA. eIF4E threshold levels differ in governing normal and neoplastic expansion of mammary stem and luminal progenitor cells. Cancer Research. 75: 687-97. PMID 25524901 DOI: 10.1158/0008-5472.Can-14-2571 |
0.353 |
|
| 2015 |
Yee D. A tale of two receptors: insulin and insulin-like growth factor signaling in cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 667-9. PMID 25303978 DOI: 10.1158/1078-0432.Ccr-14-2056 |
0.506 |
|
| 2015 |
Daniel AR, Gaviglio AL, Knutson TP, Ostrander JH, D'Assoro AB, Ravindranathan P, Peng Y, Raj GV, Yee D, Lange CA. Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes. Oncogene. 34: 506-15. PMID 24469035 DOI: 10.1038/Onc.2013.579 |
0.565 |
|
| 2015 |
Guo Z, Chu H, Berger AC, Tuttle TM, Zera R, Guttormson N, Nowak D, Bowers BJ, Kerr E, Boulanger K, Mordenti M, Miller JS, Yee D, Potter D. Effects of lumpectomy or mastectomy on plasma epoxyeicosatrienoic acid levels in patients with estrogen receptor positive, HER2-negative breast cancer. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E11563 |
0.46 |
|
| 2015 |
Tripathy D, Chien AJ, Hylton N, Buxton MB, Ewing CA, Wallace AM, Forero A, Kaplan HG, Nanda R, Albain KS, Moulder SL, Haley BB, DeMichele A, Symmans WF, Veer Lv', ... ... Yee D, et al. Adaptively randomized trial of neoadjuvant chemotherapy with or without the Akt inhibitor MK-2206: Graduation results from the I-SPY 2 Trial. Journal of Clinical Oncology. 33: 524-524. DOI: 10.1200/Jco.2015.33.15_Suppl.524 |
0.319 |
|
| 2015 |
Zhang X, Varma S, Yee D. Abstract P6-12-05: Inducible suppression of insulin receptor substrate I inhibits IGF-I/insulin/estradiol dependent cell growth in MCF-7L breast cancer cells Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P6-12-05 |
0.607 |
|
| 2015 |
Bartelink IH, Prideaux B, Hann B, Krings G, Coppe J, Swigart-Brown L, Lee PRE, Esserman L, Yee D, Wolf D, Savic RM, Veer Lvt. Abstract P6-11-02: Spatial distribution of veliparib measured by matrix assisted laser desorption ionization mass spectrometry in triple negative breast cancer tumors Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P6-11-02 |
0.36 |
|
| 2015 |
Beckwith HC, Yee D. Abstract P4-06-06: Growth hormone induction of oncogenic signaling promotes survival of endocrine resistant breast cancer cells Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P4-06-06 |
0.606 |
|
| 2015 |
LaPara K, Yee D. Abstract P4-06-03: Targeting the insulin receptor with a small peptide (S961) in cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P4-06-03 |
0.552 |
|
| 2015 |
Chan JY, LaPara K, Hackel B, Yee D. Abstract P4-06-02: Insulin receptor targeting in breast cancer through yeast surface display Cancer Research. 75: 1881-1881. DOI: 10.1158/1538-7445.Sabcs14-P4-06-02 |
0.627 |
|
| 2015 |
Wulfkuhle JD, Yau C, Wolf DM, Gallagher RI, Sanil A, Brown-Swigart L, Flynn S, Hirst G, Investigators IT, Buxton M, DeMichele A, Hylton N, Symmans WF, Veer Lv, Yee D, et al. Abstract P3-06-15: Evaluation of HER family protein signaling network as a predictive biomarker for pCR for breast cancer patients treated with neratinib in the I-SPY 2 trial Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-06-15 |
0.365 |
|
| 2015 |
Yang Y, Yee D. Abstract 1207: Nrf2 suppression results in growth inhibition and enhances response to chemotherapy and radiation therapy in triple-negative breast cancer cells Cancer Research. 75: 1207-1207. DOI: 10.1158/1538-7445.Am2015-1207 |
0.545 |
|
| 2015 |
Park H, Huang X, Greene J, Pao J, Mulvey E, Zhou SX, Sachdev D, Yee D, Rader C, Albert CM, Hamby C, Loeb D, Cairo MS, Zhou X. IGF1R- and ROR1-Specific Chimeric Antigen Receptor (CAR) T Cell Immunotherapy for Poor Risk Sarcomas Biology of Blood and Marrow Transplantation. 21: S52-S53. DOI: 10.1016/J.Bbmt.2014.11.686 |
0.301 |
|
| 2014 |
Prideaux B, Hann B, Krings G, Coppe JP, Brown Swigart L, Lee EP, Esserman L, Yee D, Wolf D, Savic RM. Spatial distribution of veliparib measured by matrix-assisted laser desorption ionization mass spectrometry in triple-negative breast cancer tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 161. PMID 28141099 DOI: 10.1200/Jco.2014.32.26_Suppl.161 |
0.37 |
|
| 2014 |
Beckwith H, Yee D. Insulin-like growth factors, insulin, and growth hormone signaling in breast cancer: implications for targeted therapy. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 20: 1214-21. PMID 25297664 DOI: 10.4158/Ep14208.Ra |
0.602 |
|
| 2014 |
Partridge AH, Rumble RB, Carey LA, Come SE, Davidson NE, Di Leo A, Gralow J, Hortobagyi GN, Moy B, Yee D, Brundage SB, Danso MA, Wilcox M, Smith IE. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 3307-29. PMID 25185096 DOI: 10.1200/Jco.2014.56.7479 |
0.5 |
|
| 2014 |
Yang Y, Yee D. IGF-I regulates redox status in breast cancer cells by activating the amino acid transport molecule xC-. Cancer Research. 74: 2295-305. PMID 24686172 DOI: 10.1158/0008-5472.Can-13-1803 |
0.607 |
|
| 2014 |
Buxton MB, Natsuhara K, DeMichele A, Perlmutter J, Hylton NM, Yee D, Veer Lv, Symmans WF, Hogarth M, Lyandres J, Davis SE, Flynn S, Paoloni M, Berry DA, Esserman L. Transforming the clinical trial process: The I-SPY 2 trial as a model for improving the efficiency of clinical trials and accelerating the drug-screening process. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps2633 |
0.346 |
|
| 2014 |
Park JW, Liu MC, Yee D, DeMichele A, Veer Lv', Hylton N, Symmans F, Buxton MB, Chien AJ, Wallace A, Melisko M, Schwab R, Boughey J, Tripathy D, Kaplan H, et al. Abstract CT227: Neratinib plus standard neoadjuvant therapy for high-risk breast cancer: Efficacy results from the I-SPY 2 TRIAL Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Ct227 |
0.403 |
|
| 2014 |
Glas A, Peeters J, Yau C, Wolf D, Sanil A, Li Y, Severson T, Linn S, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, et al. 532 Evaluation of a BRCAness signature as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 trial European Journal of Cancer. 50: 173. DOI: 10.1016/S0959-8049(14)70658-6 |
0.39 |
|
| 2013 |
Xu W, Banerji S, Davie JR, Kassie F, Yee D, Kratzke R. Yin Yang gene expression ratio signature for lung cancer prognosis. Plos One. 8: e68742. PMID 23874744 DOI: 10.1371/Journal.Pone.0068742 |
0.337 |
|
| 2013 |
Zhang X, Diaz MR, Yee D. Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells. Breast Cancer Research and Treatment. 139: 351-60. PMID 23686416 DOI: 10.1007/S10549-013-2541-Y |
0.488 |
|
| 2013 |
Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, Refsland EW, Kotandeniya D, Tretyakova N, Nikas JB, Yee D, Temiz NA, Donohue DE, McDougle RM, Brown WL, et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature. 494: 366-70. PMID 23389445 DOI: 10.1038/Nature11881 |
0.411 |
|
| 2013 |
Forsman CL, Ng BC, Heinze RK, Kuo C, Sergi C, Gopalakrishnan R, Yee D, Graf D, Schwertfeger KL, Petryk A. BMP-binding protein twisted gastrulation is required in mammary gland epithelium for normal ductal elongation and myoepithelial compartmentalization Developmental Biology. 373: 95-106. PMID 23103586 DOI: 10.1016/J.Ydbio.2012.10.007 |
0.366 |
|
| 2013 |
Yang Y, Fagan D, Anderson LF, LaPara K, Zhang X, Ochnik A, Chan JY, Beckwith H, Yee D. Abstract IA17: Targeting downstream effectors of growth factor signaling Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-Ia17 |
0.824 |
|
| 2013 |
Ochnik AM, Peterson MS, Avdulov SV, Yee D. Abstract B121: AIB1 is a transcriptional and translational mediator of breast cancer cell growth and migration targets Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-B121 |
0.559 |
|
| 2013 |
Yang Y, Becker MA, Yee D. Abstract 535: IGF-I stimulates amino acid transporter xC- function to reduce intracellular ROS level and promote proliferation in human breast cancer cells. Cancer Research. 73: 535-535. DOI: 10.1158/1538-7445.Am2013-535 |
0.762 |
|
| 2013 |
Daniel AR, Gaviglio AL, Knutson TP, Ostrander JH, Yee D, Lange CA. Abstract 3572: Unliganded progesterone receptors augment estrogen-induced growth of breast cancer cells via co-regulation of estrogen receptor target genes. Cancer Research. 73: 3572-3572. DOI: 10.1158/1538-7445.Am2013-3572 |
0.55 |
|
| 2013 |
Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, Refsland EW, Kotandeniya D, Tretyakova N, Nikas JB, Yee D, Temiz NA, Donohue DE, McDougle RM, Brown WL, et al. Correction: Corrigendum: APOBEC3B is an enzymatic source of mutation in breast cancer Nature. 502: 580-580. DOI: 10.1038/Nature12667 |
0.386 |
|
| 2012 |
Yang Y, Yee D. Targeting insulin and insulin-like growth factor signaling in breast cancer. Journal of Mammary Gland Biology and Neoplasia. 17: 251-61. PMID 23054135 DOI: 10.1007/S10911-012-9268-Y |
0.565 |
|
| 2012 |
Yee D. Insulin-like growth factor receptor inhibitors: baby or the bathwater? Journal of the National Cancer Institute. 104: 975-81. PMID 22761272 DOI: 10.1093/Jnci/Djs258 |
0.515 |
|
| 2012 |
Ochnik AM, Yee D. Estrogen-related receptor alpha: an orphan finds a family. Breast Cancer Research : Bcr. 14: 309. PMID 22574877 DOI: 10.1186/Bcr3124 |
0.484 |
|
| 2012 |
Fagan DH, Uselman RR, Sachdev D, Yee D. Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment. Cancer Research. 72: 3372-80. PMID 22573715 DOI: 10.1158/0008-5472.Can-12-0684 |
0.819 |
|
| 2012 |
Potter DA, Yee D, Guo Z, Rodriguez M. Should diabetic women with breast cancer have their own intervention studies? Endocrine-Related Cancer. 19: C13-7. PMID 22180498 DOI: 10.1530/Erc-11-0309 |
0.399 |
|
| 2012 |
Khatri A, Brundage RC, Hull JM, Williams BW, Yee D, Kirstein MN. Pharmacodynamic modeling of sequence-dependent antitumor activity of insulin-like growth factor blockade and gemcitabine. The Aaps Journal. 14: 1-9. PMID 22101930 DOI: 10.1208/S12248-011-9308-3 |
0.489 |
|
| 2012 |
Gu D, Turesky RJ, Tao Y, Langouët SA, Nauwelaërs GC, Yuan JM, Yee D, Yu MC. DNA adducts of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 4-aminobiphenyl are infrequently detected in human mammary tissue by liquid chromatography/tandem mass spectrometry. Carcinogenesis. 33: 124-30. PMID 22072616 DOI: 10.1093/Carcin/Bgr252 |
0.381 |
|
| 2012 |
Tuttle TM, Jarosek S, Habermann EB, Yee D, Yuan J, Virnig BA. Omission of radiation therapy after breast-conserving surgery in the United States: a population-based analysis of clinicopathologic factors. Cancer. 118: 2004-13. PMID 21952948 DOI: 10.1002/Cncr.26505 |
0.475 |
|
| 2012 |
Zeng X, Zhang H, Oh A, Zhang Y, Yee D. Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor. Breast Cancer Research and Treatment. 133: 117-26. PMID 21850397 DOI: 10.1007/S10549-011-1713-X |
0.814 |
|
| 2012 |
Fagan DH, Uselman RR, Sachdev D, Yee D. Expression of type I insulin-like growth factor receptor (IGF1R) in tamoxifen-resistant cells: Implications for cotargeting of IGF1R and estrogen receptor (ER) in breast cancer. Journal of Clinical Oncology. 30: e13590-e13590. DOI: 10.1200/Jco.2012.30.15_Suppl.E13590 |
0.83 |
|
| 2012 |
Bolan P, Wey A, Eberly L, Nelson M, Haddad T, Yee D, Garwood M. Abstract P1-14-11: Assessing Prognosis and Therapy Response in Primary Systemic Therapy of Breast Cancer with Magnetic Resonance Spectroscopy Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P1-14-11 |
0.391 |
|
| 2011 |
Yee D, Chen L, Goren A, Lorenzo R. Physicians' perspectives on treatment options and outcomes in metastatic triple-negative breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e11542. PMID 28021647 DOI: 10.1200/jco.2011.29.15_suppl.e11542 |
0.355 |
|
| 2011 |
Lange CA, Yee D. Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer. Endocrine-Related Cancer. 18: C19-24. PMID 21613412 DOI: 10.1530/Erc-11-0112 |
0.555 |
|
| 2011 |
Zhang H, Uselman RR, Yee D. Exogenous near-infrared fluorophores and their applications in cancer diagnosis: biological and clinical perspectives. Expert Opinion On Medical Diagnostics. 5: 241-51. PMID 21566703 DOI: 10.1517/17530059.2011.566858 |
0.339 |
|
| 2011 |
Becker MA, Ibrahim YH, Cui X, Lee AV, Yee D. The IGF pathway regulates ERα through a S6K1-dependent mechanism in breast cancer cells. Molecular Endocrinology (Baltimore, Md.). 25: 516-28. PMID 21292829 DOI: 10.1210/me.2010-0373 |
0.745 |
|
| 2011 |
Guo Z, Mitra R, Milani M, Rodriguez M, Yee D, Sachdev D, Potter DA. Abstract 2288: CYP3A4 monoxygenase regulates IGF-1 signaling in ER-positive breast cancer cells Cancer Research. 71: 2288-2288. DOI: 10.1158/1538-7445.Am2011-2288 |
0.511 |
|
| 2010 |
Cochrane DR, Cittelly DM, Howe EN, Spoelstra NS, McKinsey EL, LaPara K, Elias A, Yee D, Richer JK. MicroRNAs Link Estrogen Receptor Alpha Status and Dicer Levels in Breast Cancer Hormones and Cancer. 1: 306-319. PMID 21761362 DOI: 10.1007/S12672-010-0043-5 |
0.358 |
|
| 2010 |
Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. Diabetes Care. 33: 1674-85. PMID 20587728 DOI: 10.2337/Dc10-0666 |
0.372 |
|
| 2010 |
Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. Ca: a Cancer Journal For Clinicians. 60: 207-21. PMID 20554718 DOI: 10.3322/Caac.20078 |
0.318 |
|
| 2010 |
Yee D. How to train your biomarker. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 3091-3. PMID 20530694 DOI: 10.1158/1078-0432.Ccr-10-0873 |
0.502 |
|
| 2010 |
Yee D. Adaptor proteins as targets for cancer prevention. Cancer Prevention Research (Philadelphia, Pa.). 3: 263-5. PMID 20179300 DOI: 10.1158/1940-6207.Capr-10-0008 |
0.474 |
|
| 2010 |
Zhang H, Fagan DH, Zeng X, Freeman KT, Sachdev D, Yee D. Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. Oncogene. 29: 2517-27. PMID 20154728 DOI: 10.1038/Onc.2010.17 |
0.825 |
|
| 2010 |
Blaes AH, Gaillard P, Peterson BA, Yee D, Virnig B. Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy Breast Cancer Research and Treatment. 122: 585-590. PMID 20058065 DOI: 10.1007/S10549-009-0730-5 |
0.357 |
|
| 2010 |
Sachdev D, Zhang X, Matise I, Gaillard-Kelly M, Yee D. The type i insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival Oncogene. 29: 251-262. PMID 19838209 DOI: 10.1038/Onc.2009.316 |
0.482 |
|
| 2010 |
Rodriguez M, Mitra R, Guo Z, Becker MA, Yee D, Potter DA. Abstract 4129: Effects of the metabolism of omega-3 fatty acid EPA by CYP1A1 in breast cancer proliferation and survival Cancer Research. 70: 4129-4129. DOI: 10.1158/1538-7445.Am10-4129 |
0.724 |
|
| 2009 |
Yee D. Targeting the insulin-like growth factor receptor. Clinical Advances in Hematology & Oncology : H&O. 7: 452-4. PMID 19701152 |
0.347 |
|
| 2009 |
Zhang H, Zeng X, Li Q, Gaillard-Kelly M, Wagner CR, Yee D. Fluorescent tumour imaging of type I IGF receptor in vivo: comparison of antibody-conjugated quantum dots and small-molecule fluorophore. British Journal of Cancer. 101: 71-9. PMID 19491901 DOI: 10.1038/Sj.Bjc.6605103 |
0.76 |
|
| 2009 |
Zeng X, Sachdev D, Zhang H, Gaillard-Kelly M, Yee D. Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 2840-9. PMID 19351773 DOI: 10.1158/1078-0432.Ccr-08-1401 |
0.797 |
|
| 2009 |
Zhang H, Sachdev D, Wang C, Hubel A, Gaillard-Kelly M, Yee D. Detection and downregulation of type I IGF receptor expression by antibody-conjugated quantum dots in breast cancer cells. Breast Cancer Research and Treatment. 114: 277-85. PMID 18418709 DOI: 10.1007/S10549-008-0014-5 |
0.557 |
|
| 2009 |
Haddadin IS, McIntosh A, Meisamy S, Corum C, Styczynski Snyder AL, Powell NJ, Nelson MT, Yee D, Garwood M, Bolan PJ. Metabolite quantification and high-field MRS in breast cancer. Nmr in Biomedicine. 22: 65-76. PMID 17957820 DOI: 10.1002/Nbm.1217 |
0.436 |
|
| 2009 |
Yee D, Fagan DH, Zhang X, Oh AS, LaPara K, Becker M, Sachdev D, Zhang H. Abstract CN07-02: Disrupting insulin‐like growth factor signaling with monoclonal antibodies Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-Cn07-02 |
0.833 |
|
| 2009 |
Yee D, Zhang X, LaPara K, Fagan D, Ibrahim Y, Zhang H, Zeng X, Becker M, Sachdev D. 58 Inhibition of IGF signalling as cancer therapy European Journal of Cancer Supplements. 7: 17. DOI: 10.1016/S1359-6349(09)70061-8 |
0.793 |
|
| 2008 |
Lange CA, Yee D. Progesterone and breast cancer. Women's Health (London, England). 4: 151-62. PMID 19072517 DOI: 10.2217/17455057.4.2.151 |
0.509 |
|
| 2008 |
Yee D, Wood TL. The IGF system in mammary development and breast cancer. Preface. Journal of Mammary Gland Biology and Neoplasia. 13: 351-2. PMID 19030973 DOI: 10.1007/S10911-008-9096-2 |
0.596 |
|
| 2008 |
Fagan DH, Yee D. Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. Journal of Mammary Gland Biology and Neoplasia. 13: 423-9. PMID 19003523 DOI: 10.1007/S10911-008-9098-0 |
0.803 |
|
| 2008 |
Ibrahim YH, Byron SA, Cui X, Lee AV, Yee D. Progesterone receptor-B regulation of insulin-like growth factor-stimulated cell migration in breast cancer cells via insulin receptor substrate-2. Molecular Cancer Research : McR. 6: 1491-8. PMID 18819936 DOI: 10.1158/1541-7786.Mcr-07-2173 |
0.775 |
|
| 2008 |
Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, Rinehart C, Seidel B, Yee D, Arteaga CL, Engelman JA. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. The Journal of Clinical Investigation. 118: 2609-19. PMID 18568074 DOI: 10.1172/Jci34588 |
0.465 |
|
| 2008 |
Zhang H, Yee D, Wang C. Quantum dots for cancer diagnosis and therapy: biological and clinical perspectives. Nanomedicine (London, England). 3: 83-91. PMID 18393668 DOI: 10.2217/17435889.3.1.83 |
0.364 |
|
| 2008 |
Haddad TC, Yee D. Of mice and (wo)men: is this any way to test a new drug? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 830-2. PMID 18281652 DOI: 10.1200/Jco.2007.14.9062 |
0.51 |
|
| 2008 |
Kirstein MN, Brundage RC, Moore MM, Williams BW, Hillman LA, Dagit JW, Fisher JE, Marker PH, Kratzke RA, Yee D. Pharmacodynamic characterization of gemcitabine cytotoxicity in an in vitro cell culture bioreactor system. Cancer Chemotherapy and Pharmacology. 61: 291-9. PMID 17429628 DOI: 10.1007/S00280-007-0474-Z |
0.404 |
|
| 2007 |
Zeng X, Yee D. Insulin-like growth factors and breast cancer therapy. Advances in Experimental Medicine and Biology. 608: 101-12. PMID 17993235 DOI: 10.1007/978-0-387-74039-3_7 |
0.84 |
|
| 2007 |
Kirstein MN, Wieman KM, Williams BW, Fisher JE, Marker PH, Le CT, Yee D, Kratzke RA. Short versus continuous gemcitabine treatment of non-small cell lung cancer in an in vitro cell culture bioreactor system. Lung Cancer (Amsterdam, Netherlands). 58: 196-204. PMID 17651859 DOI: 10.1016/J.Lungcan.2007.06.005 |
0.342 |
|
| 2007 |
Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Molecular Cancer Therapeutics. 6: 1-12. PMID 17237261 DOI: 10.1158/Aacr.Edb-Mct-06-0080 |
0.577 |
|
| 2007 |
Zhang H, Pelzer AM, Kiang DT, Yee D. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Research. 67: 391-7. PMID 17210722 DOI: 10.1158/0008-5472.Can-06-1712 |
0.616 |
|
| 2007 |
Kleinberg DL, Ruan W, Yee D, Kovacs KT, Vidal S. Insulin-like growth factor (IGF)-I controls prostate fibromuscular development: IGF-I inhibition prevents both fibromuscular and glandular development in eugonadal mice. Endocrinology. 148: 1080-8. PMID 17138659 DOI: 10.1210/En.2006-1272 |
0.387 |
|
| 2006 |
Zhang H, Yee D. Is the type I insulin-like growth factor receptor a therapeutic target in endometrial cancer? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 6323-5. PMID 17085640 DOI: 10.1158/1078-0432.Ccr-06-1707 |
0.49 |
|
| 2006 |
Byron SA, Horwitz KB, Richer JK, Lange CA, Zhang X, Yee D. Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells. British Journal of Cancer. 95: 1220-8. PMID 17043687 DOI: 10.1038/Sj.Bjc.6603354 |
0.782 |
|
| 2006 |
Sachdev D, Yee D. Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer. Journal of Mammary Gland Biology and Neoplasia. 11: 27-39. PMID 16947084 DOI: 10.1007/S10911-006-9010-8 |
0.589 |
|
| 2006 |
Whitson BA, Jacobson BA, Frizelle S, Patel MR, Yee D, Maddaus MA, Kratzke RA. Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma. Thoracic Surgery Directors Association Resident Research Award. The Annals of Thoracic Surgery. 82: 996-1001; discussion. PMID 16928523 DOI: 10.1016/J.Athoracsur.2006.04.013 |
0.477 |
|
| 2006 |
Ahmed RL, Thomas W, Yee D, Schmitz KH. Randomized controlled trial of weight training and lymphedema in breast cancer survivors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 2765-72. PMID 16702582 DOI: 10.1200/Jco.2005.03.6749 |
0.432 |
|
| 2006 |
Haddad T, Yee D. Targeting the insulin-like growth factor axis as a cancer therapy. Future Oncology (London, England). 2: 101-10. PMID 16556077 DOI: 10.2217/14796694.2.1.101 |
0.511 |
|
| 2006 |
Farooqui M, Geng ZH, Stephenson EJ, Zaveri N, Yee D, Gupta K. Naloxone acts as an antagonist of estrogen receptor activity in MCF-7 cells. Molecular Cancer Therapeutics. 5: 611-20. PMID 16546975 DOI: 10.1158/1535-7163.Mct-05-0016 |
0.454 |
|
| 2006 |
Sachdev D, Singh R, Fujita-Yamaguchi Y, Yee D. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer. Cancer Research. 66: 2391-402. PMID 16489046 DOI: 10.1158/0008-5472.Can-05-3126 |
0.543 |
|
| 2006 |
Yee D. Targeting insulin-like growth factor pathways. British Journal of Cancer. 94: 465-8. PMID 16450000 DOI: 10.1038/Sj.Bjc.6602963 |
0.579 |
|
| 2005 |
Miller BS, Yee D. Type I insulin-like growth factor receptor as a therapeutic target in cancer. Cancer Research. 65: 10123-7. PMID 16287993 DOI: 10.1158/0008-5472.Can-05-2752 |
0.511 |
|
| 2005 |
Zhang X, Lin M, van Golen KL, Yoshioka K, Itoh K, Yee D. Multiple signaling pathways are activated during insulin-like growth factor-I (IGF-I) stimulated breast cancer cell migration. Breast Cancer Research and Treatment. 93: 159-68. PMID 16187236 DOI: 10.1007/S10549-005-4626-8 |
0.564 |
|
| 2005 |
Meisamy S, Bolan PJ, Baker EH, Pollema MG, Le CT, Kelcz F, Lechner MC, Luikens BA, Carlson RA, Brandt KR, Amrami KK, Nelson MT, Everson LI, Emory TH, Tuttle TM, ... Yee D, et al. Adding in vivo quantitative 1H MR spectroscopy to improve diagnostic accuracy of breast MR imaging: preliminary results of observer performance study at 4.0 T. Radiology. 236: 465-75. PMID 16040903 DOI: 10.1148/Radiol.2362040836 |
0.316 |
|
| 2005 |
Schmitz KH, Ahmed RL, Hannan PJ, Yee D. Safety and efficacy of weight training in recent breast cancer survivors to alter body composition, insulin, and insulin-like growth factor axis proteins. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 14: 1672-80. PMID 16030100 DOI: 10.1158/1055-9965.Epi-04-0736 |
0.492 |
|
| 2005 |
Bolan PJ, Nelson MT, Yee D, Garwood M. Imaging in breast cancer: Magnetic resonance spectroscopy. Breast Cancer Research : Bcr. 7: 149-52. PMID 15987466 DOI: 10.1186/Bcr1202 |
0.39 |
|
| 2005 |
Ibrahim YH, Yee D. Insulin-like growth factor-I and breast cancer therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 944s-50s. PMID 15701891 |
0.541 |
|
| 2005 |
Come SE, Buzdar AU, Ingle JN, Arteaga CL, Brodie AM, Colditz GA, Johnston SR, Kristensen VN, Lønning PE, McDonnell DP, Osborne CK, Russo J, Santen RJ, Yee D, Hart CS. Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 861s-4s. PMID 15701878 |
0.372 |
|
| 2004 |
Zhang H, Yee D. The therapeutic potential of agents targeting the type I insulin-like growth factor receptor. Expert Opinion On Investigational Drugs. 13: 1569-77. PMID 15566314 DOI: 10.1517/13543784.13.12.1569 |
0.539 |
|
| 2004 |
Meisamy S, Bolan PJ, Baker EH, Bliss RL, Gulbahce E, Everson LI, Nelson MT, Emory TH, Tuttle TM, Yee D, Garwood M. Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy--a pilot study at 4 T. Radiology. 233: 424-31. PMID 15516615 DOI: 10.1148/Radiol.2332031285 |
0.401 |
|
| 2004 |
Hoang CD, Zhang X, Scott PD, Guillaume TJ, Maddaus MA, Yee D, Kratzke RA. Selective activation of insulin receptor substrate-1 and -2 in pleural mesothelioma cells: association with distinct malignant phenotypes. Cancer Research. 64: 7479-85. PMID 15492273 DOI: 10.1158/0008-5472.Can-04-1898 |
0.488 |
|
| 2004 |
Ibrahim YH, Yee D. Insulin-like growth factor-I and cancer risk. Growth Hormone & Igf Research : Official Journal of the Growth Hormone Research Society and the International Igf Research Society. 14: 261-9. PMID 15231294 DOI: 10.1016/J.Ghir.2004.01.005 |
0.509 |
|
| 2004 |
Avdulov S, Li S, Michalek V, Burrichter D, Peterson M, Perlman DM, Manivel JC, Sonenberg N, Yee D, Bitterman PB, Polunovsky VA. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell. 5: 553-63. PMID 15193258 DOI: 10.1016/J.Ccr.2004.05.024 |
0.399 |
|
| 2004 |
Zhang X, Kamaraju S, Hakuno F, Kabuta T, Takahashi S, Sachdev D, Yee D. Motility response to insulin-like growth factor-I (IGF-I) in MCF-7 cells is associated with IRS-2 activation and integrin expression. Breast Cancer Research and Treatment. 83: 161-70. PMID 14997047 DOI: 10.1023/B:Brea.0000010709.31256.C6 |
0.502 |
|
| 2004 |
Sachdev D, Hartell JS, Lee AV, Zhang X, Yee D. A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. The Journal of Biological Chemistry. 279: 5017-24. PMID 14615489 DOI: 10.1074/Jbc.M305403200 |
0.568 |
|
| 2004 |
Schmitz KH, Ahmed RL, Yee D. Effect of Strength Training on Insulin and Insulin-like Growth Factors in Breast Cancer Survivors Medicine and Science in Sports and Exercise. 36. DOI: 10.1097/00005768-200405001-01442 |
0.517 |
|
| 2003 |
Zhang X, Yee D. The type I IGF receptor as a target for breast cancer therapy. Breast Disease. 17: 115-24. PMID 15687682 DOI: 10.3233/Bd-2003-17111 |
0.628 |
|
| 2003 |
Ye JJ, Liang SJ, Guo N, Li SL, Wu AM, Giannini S, Sachdev D, Yee D, Brünner N, Ikle D, Fujita-Yamaguchi Y. Combined effects of tamoxifen and a chimeric humanized single chain antibody against the type I IGF receptor on breast tumor growth in vivo. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme. 35: 836-42. PMID 14710366 DOI: 10.1055/S-2004-814145 |
0.45 |
|
| 2003 |
Bolan PJ, Meisamy S, Baker EH, Lin J, Emory T, Nelson M, Everson LI, Yee D, Garwood M. In vivo quantification of choline compounds in the breast with 1H MR spectroscopy. Magnetic Resonance in Medicine. 50: 1134-43. PMID 14648561 DOI: 10.1002/Mrm.10654 |
0.367 |
|
| 2003 |
Byron SA, Yee D. Potential therapeutic strategies to interrupt insulin-like growth factor signaling in breast cancer. Seminars in Oncology. 30: 125-32. PMID 14613033 DOI: 10.1053/J.Seminoncol.2003.08.014 |
0.793 |
|
| 2003 |
Gross JM, Yee D. The type-1 insulin-like growth factor receptor tyrosine kinase and breast cancer: biology and therapeutic relevance. Cancer Metastasis Reviews. 22: 327-36. PMID 12884909 DOI: 10.1023/A:1023720928680 |
0.779 |
|
| 2003 |
Repka T, Chiorean EG, Gay J, Herwig KE, Kohl VK, Yee D, Miller JS. Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 2440-6. PMID 12855616 |
0.378 |
|
| 2003 |
Yee D. Cyclin E in breast cancer. The New England Journal of Medicine. 348: 1063-4; author reply. PMID 12638588 |
0.355 |
|
| 2003 |
Sachdev D, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS, Yee D. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Research. 63: 627-35. PMID 12566306 |
0.532 |
|
| 2003 |
Schmitz KH, Ahmed RL, Yee D. Effects Of Weight Training On Body Composition Of Breast Cancer Survivors Medicine and Science in Sports and Exercise. 35. DOI: 10.1097/00005768-200305001-02094 |
0.387 |
|
| 2003 |
Ahmed RL, Schmitz KH, Yee D. Strength Training And Lymphedema Symptoms In Recent Breast Cancer Survivors Medicine and Science in Sports and Exercise. 35. DOI: 10.1097/00005768-200305001-01642 |
0.395 |
|
| 2002 |
Schmitz KH, Ahmed RL, Yee D. Effects of a 9-month strength training intervention on insulin, insulin-like growth factor (IGF)-I, IGF-binding protein (IGFBP)-1, and IGFBP-3 in 30-50-year-old women. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 11: 1597-604. PMID 12496050 |
0.321 |
|
| 2002 |
Bolan PJ, DelaBarre L, Baker EH, Merkle H, Everson LI, Yee D, Garwood M. Eliminating spurious lipid sidebands in 1H MRS of breast lesions. Magnetic Resonance in Medicine. 48: 215-22. PMID 12210929 DOI: 10.1002/Mrm.10224 |
0.334 |
|
| 2002 |
Zhang X, Yee D. Insulin-like growth factor binding protein-1 (IGFBP-1) inhibits breast cancer cell motility. Cancer Research. 62: 4369-75. PMID 12154042 |
0.492 |
|
| 2002 |
Yee D. The insulin-like growth factor system as a treatment target in breast cancer. Seminars in Oncology. 29: 86-95. PMID 12138402 DOI: 10.1016/S0093-7754(02)70131-0 |
0.61 |
|
| 2002 |
Gooch JL, Christy B, Yee D. STAT6 mediates interleukin-4 growth inhibition in human breast cancer cells. Neoplasia (New York, N.Y.). 4: 324-31. PMID 12082548 DOI: 10.1038/Sj.Neo.7900248 |
0.453 |
|
| 2002 |
Yee D. Are the insulin-like growth factors relevant to cancer? Growth Hormone & Igf Research : Official Journal of the Growth Hormone Research Society and the International Igf Research Society. 11: 339-45. PMID 11914021 DOI: 10.1054/Ghir.2001.0256 |
0.532 |
|
| 2002 |
Gross JM, Yee D. How does the estrogen receptor work? Breast Cancer Research : Bcr. 4: 62-4. PMID 11879565 DOI: 10.1186/Bcr424 |
0.707 |
|
| 2002 |
Ahmed RL, Schmitz KH, Yee D. Effects Of Strength Training On Body Composition, Fasting Insulin, And Insulin-Like Growth Factor-I Medicine and Science in Sports and Exercise. 34. DOI: 10.1097/00005768-200205001-00380 |
0.38 |
|
| 2001 |
Jackson JG, Zhang X, Yoneda T, Yee D. Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines. Oncogene. 20: 7318-25. PMID 11704861 DOI: 10.1038/Sj.Onc.1204920 |
0.565 |
|
| 2001 |
Sachdev D, Yee D. The IGF system and breast cancer. Endocrine-Related Cancer. 8: 197-209. PMID 11566611 DOI: 10.1677/Erc.0.0080197 |
0.573 |
|
| 2001 |
Zhao HH, Herrera RE, Coronado-Heinsohn E, Yang MC, Ludes-Meyers JH, Seybold-Tilson KJ, Nawaz Z, Yee D, Barr FG, Diab SG, Brown PH, Fuqua SAW, Osborne CK. Forkhead Homologue in Rhabdomyosarcoma Functions as a Bifunctional Nuclear Receptor-interacting Protein with Both Coactivator and Corepressor Functions Journal of Biological Chemistry. 276: 27907-27912. PMID 11353774 DOI: 10.1074/Jbc.M104278200 |
0.433 |
|
| 2001 |
Patil R, Chavez JB, Yee D. Inducible expression of herpes simplex virus thymidine kinase increases sensitivity to ganciclovir but does not enhance bystander effect in breast cancer cells. Breast Cancer Research and Treatment. 62: 109-15. PMID 11016748 DOI: 10.1023/A:1006443720829 |
0.456 |
|
| 2000 |
Zhang X, Yee D. Tyrosine kinase signalling in breast cancer: insulin-like growth factors and their receptors in breast cancer. Breast Cancer Research : Bcr. 2: 170-5. PMID 11250706 DOI: 10.1186/Bcr50 |
0.614 |
|
| 2000 |
Jackson JG, Kreisberg JI, Koterba AP, Yee D, Brattain MG. Phosphorylation and nuclear exclusion of the forkhead transcription factor FKHR after epidermal growth factor treatment in human breast cancer cells. Oncogene. 19: 4574-81. PMID 11030146 DOI: 10.1038/Sj.Onc.1203825 |
0.455 |
|
| 2000 |
Yee D, Lee AV. Crosstalk between the insulin-like growth factors and estrogens in breast cancer. Journal of Mammary Gland Biology and Neoplasia. 5: 107-15. PMID 10791773 DOI: 10.1023/A:1009575518338 |
0.585 |
|
| 2000 |
Wood TL, Yee D. Introduction: IGFs and IGFBPs in the normal mammary gland and in breast cancer Journal of Mammary Gland Biology and Neoplasia. 5: 1-5. PMID 10791763 DOI: 10.1023/A:1009580913795 |
0.542 |
|
| 2000 |
Lee AV, Gooch JL, Oesterreich S, Guler RL, Yee D. Insulin-like growth factor I-induced degradation of insulin receptor substrate 1 is mediated by the 26S proteasome and blocked by phosphatidylinositol 3'-kinase inhibition. Molecular and Cellular Biology. 20: 1489-96. PMID 10669726 DOI: 10.1128/Mcb.20.5.1489-1496.2000 |
0.488 |
|
| 2000 |
Wood TL, Yee D. IGFs and IGFBPs in the normal mammary gland and in breast cancer Journal of Mammary Gland Biology and Neoplasia. 5: 1-5. DOI: 10.1023/A:1009580913795 |
0.452 |
|
| 1999 |
Jackson JG, Yee D. IRS-1 expression and activation are not sufficient to activate downstream pathways and enable IGF-I growth response in estrogen receptor negative breast cancer cells. Growth Hormone & Igf Research : Official Journal of the Growth Hormone Research Society and the International Igf Research Society. 9: 280-9. PMID 10543935 DOI: 10.1054/Ghir.1999.0113 |
0.577 |
|
| 1999 |
Gooch JL, Van Den Berg CL, Yee D. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death--proliferative and anti-apoptotic effects. Breast Cancer Research and Treatment. 56: 1-10. PMID 10517338 DOI: 10.1023/A:1006208721167 |
0.53 |
|
| 1999 |
Durham SK, Suwanichkul A, Scheimann AO, Yee D, Jackson JG, Barr FG, Powell DR. FKHR binds the insulin response element in the insulin-like growth factor binding protein-1 promoter. Endocrinology. 140: 3140-6. PMID 10385407 DOI: 10.1210/Endo.140.7.6856 |
0.411 |
|
| 1999 |
Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK, Yee D. Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Molecular Endocrinology (Baltimore, Md.). 13: 787-96. PMID 10319328 DOI: 10.1210/Mend.13.5.0274 |
0.583 |
|
| 1998 |
Jackson JG, White MF, Yee D. Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells. The Journal of Biological Chemistry. 273: 9994-10003. PMID 9545345 DOI: 10.1074/Jbc.273.16.9994 |
0.543 |
|
| 1998 |
Lee AV, Hilsenbeck SG, Yee D. IGF system components as prognostic markers in breast cancer. Breast Cancer Research and Treatment. 47: 295-302. PMID 9516083 DOI: 10.1023/A:1005915420341 |
0.589 |
|
| 1998 |
Yee D. The insulin-like growth factors and breast cancer--revisited. Breast Cancer Research and Treatment. 47: 197-9. PMID 9516075 DOI: 10.1023/A:1005938615798 |
0.575 |
|
| 1997 |
Lee AV, Weng CN, McGuire SE, Wolf DM, Yee D. Lac Repressor Inducible Gene Expression in Human Breast Cancer Cells in Vitro and in a Xenograft Tumor Biotechniques. 23: 1062-1068. PMID 9421637 DOI: 10.2144/97236St02 |
0.512 |
|
| 1997 |
Berg CLVD, Cox GN, Stroh CA, Hilsenbeck SG, Weng CN, McDermott MJ, Pratt D, Osborne CK, Coronado-Heinsohn EB, Yee D. polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice European Journal of Cancer. 33: 1108-1113. PMID 9376191 DOI: 10.1016/S0959-8049(97)00071-3 |
0.533 |
|
| 1997 |
Dong LQ, Du H, Porter SG, Kolakowski LF, Lee AV, Mandarino J, Fan J, Yee D, Liu F. Cloning, chromosome localization, expression, and characterization of an Src homology 2 and pleckstrin homology domain-containing insulin receptor binding protein hGrb10γ Journal of Biological Chemistry. 272: 29104-29112. PMID 9360986 DOI: 10.1074/Jbc.272.46.29104 |
0.46 |
|
| 1996 |
Yee D, Berg CVD, Kozelsky T, Kuhn J, Cox G. Pharmacokinetic profile of recombination human insulin-like growth factor binding protein-1 in athymic mice. Biomedicine & Pharmacotherapy. 50: 154-157. PMID 8881372 DOI: 10.1016/0753-3322(96)85290-5 |
0.425 |
|
| 1996 |
Yee D, McGuire SE, Brünner N, Kozelsky TW, Allred DC, Chen SH, Woo SLC. Adenovirus-Mediated Gene Transfer of Herpes Simplex Virus Thymidine Kinase in an Ascites Model of Human Breast Cancer Human Gene Therapy. 7: 1251-1257. PMID 8793549 DOI: 10.1089/Hum.1996.7.10-1251 |
0.444 |
|
| 1996 |
Lee AV, Yee D. Insulin-like growth factors and breast cancer. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 49: 415-21. PMID 8746077 DOI: 10.1016/0753-3322(96)82678-3 |
0.62 |
|
| 1996 |
Grellier P, Sabbah M, Fouqueray B, Woodruff K, Yee D, Abboud HE, Abboud SL. Characterization of insulin-like growth factor binding proteins and regulation of IGFBP3 in human mesangial cells. Kidney International. 49: 1071-8. PMID 8691727 DOI: 10.1038/Ki.1996.156 |
0.406 |
|
| 1996 |
Grellier P, Feliers D, Yee D, Woodruff K, Abboud SL. Interaction between insulin-like growth factor-I and insulin-like growth factor-binding proteins in TC-1 stromal cells. Journal of Endocrinology. 149: 519-529. PMID 8691111 DOI: 10.1677/Joe.0.1490519 |
0.448 |
|
| 1996 |
Rocha RL, Hilsenbeck SG, Jackson JG, Lee AV, Figueroa JA, Yee D. Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors with poor prognostic features. Journal of the National Cancer Institute. 88: 601-6. PMID 8609661 DOI: 10.1093/Jnci/88.9.601 |
0.55 |
|
| 1996 |
Cheng HL, Randolph A, Yee D, Delafontaine P, Tennekoon G, Feldman EL. Characterization of insulin-like growth factor-I and its receptor and binding proteins in transected nerves and cultured Schwann cells. Journal of Neurochemistry. 66: 525-36. PMID 8592122 DOI: 10.1046/J.1471-4159.1996.66020525.X |
0.452 |
|
| 1995 |
Figueroa JA, Lee AV, Jackson JG, Yee D. Proliferation of cultured human prostate cancer cells is inhibited by insulin-like growth factor (IGF) binding protein-1: evidence for an IGF-II autocrine growth loop. The Journal of Clinical Endocrinology and Metabolism. 80: 3476-82. PMID 8530586 DOI: 10.1210/Jcem.80.12.8530586 |
0.477 |
|
| 1995 |
Grellier P, Yee D, Gonzalez M, Abboud SL. Characterization of insulin-like growth factor binding proteins (IGFBP) and regulation of IGFBP-4 in bone marrow stromal cells British Journal of Haematology. 90: 249-257. PMID 7540852 DOI: 10.1111/J.1365-2141.1995.Tb05144.X |
0.446 |
|
| 1995 |
Yee D. The insulin-like growth factor system as a target in breast cancer. Breast Cancer Research and Treatment. 32: 85-95. PMID 7529598 DOI: 10.1007/Bf00666209 |
0.63 |
|
| 1994 |
Yee D, Jackson JG, Von Hoff DD, Ravdin PM. Case report: use of insulin-like growth factor-I gene expression to distinguish between breast and ovarian cancer. The American Journal of the Medical Sciences. 307: 108-11. PMID 8141135 DOI: 10.1097/00000441-199402000-00007 |
0.557 |
|
| 1994 |
Yee D, Sharma J, Hilsenbeck SG. Prognostic Significance of Insulin-like Growth Factor-Binding Protein Expression in Axillary Lymph Node-Negative Breast Cancer Journal of the National Cancer Institute. 86: 1785-1789. PMID 7525978 DOI: 10.1093/Jnci/86.23.1785 |
0.535 |
|
| 1994 |
McGuire SE, Hilsenbeck SG, Figueroa JA, Jackson JG, Yee D. Detection of insulin-like growth factor binding proteins (IGFBPs) by ligand blotting in breast cancer tissues. Cancer Letters. 77: 25-32. PMID 7512885 DOI: 10.1016/0304-3835(94)90343-3 |
0.537 |
|
| 1994 |
Figueroa J, Yee D. Insulin-like growth factor binding proteins: Potential inhibitors of cancer cell growth Drugs of the Future. 19: 477. DOI: 10.1358/Dof.1994.019.05.595581 |
0.503 |
|
| 1993 |
Brünner N, Yee D, Kern FG, Spang-Thomsen M, Lippman ME, Cullen KJ. Effect of endocrine therapy on growth of T61 human breast cancer xenografts is directly correlated to a specific down-regulation of insulin-like growth factor II (IGF-II). European Journal of Cancer (Oxford, England : 1990). 562-9. PMID 8435211 DOI: 10.1016/S0959-8049(05)80152-2 |
0.483 |
|
| 1993 |
Voravud N, Lippman SM, Weber RS, Rodriquez GI, Yee D, Dimery IW, Earley CL, Hoff DDV, Hong WK. Phase II trial of 13-cis-retinoic acid plus interferon-α in recurrent head and neck cancer Investigational New Drugs. 11: 57-60. PMID 8349437 DOI: 10.1007/Bf00873912 |
0.307 |
|
| 1993 |
Sarosdy MF, Hutzler DH, Yee D, Hoff DDV. In vitro sensitivity testing of human bladder cancers and cell lines to TP-40, a hybrid protein with selective targeting and cytotoxicity. The Journal of Urology. 150: 1950-1955. PMID 8230543 DOI: 10.1016/S0022-5347(17)35944-X |
0.47 |
|
| 1993 |
Figueroa JA, Sharma J, Jackson JG, McDermott MJ, Hilsenbeck SG, Yee D. Recombinant insulin-like growth factor binding protein-1 inhibits IGF-I, serum, and estrogen-dependent growth of MCF-7 human breast cancer cells. Journal of Cellular Physiology. 157: 229-36. PMID 7693722 DOI: 10.1002/Jcp.1041570204 |
0.546 |
|
| 1993 |
Randolph A, Yee D, Feldman EL. Insulin-like growth factor binding protein expression in human retinal pigment epithelial cells Annals of the New York Academy of Sciences. 692: 265-267. PMID 7692792 DOI: 10.1111/J.1749-6632.1993.Tb26229.X |
0.418 |
|
| 1993 |
Feldman EL, Randolph A, Yee D. Insulin-like growth factor binding protein expression in SH-SY5Y neuroblastoma cells Annals of the New York Academy of Sciences. 692: 262-264. PMID 7692791 DOI: 10.1111/J.1749-6632.1993.Tb26228.X |
0.438 |
|
| 1993 |
Figueroa JA, Jackson JG, McGuire WL, Krywicki RF, Yee D. Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status. Journal of Cellular Biochemistry. 52: 196-205. PMID 7690042 DOI: 10.1002/Jcb.240520211 |
0.578 |
|
| 1993 |
Figueroa JA, Yee D, McGuire WL. Prognostic indicators in early breast cancer American Journal of the Medical Sciences. 305: 176-182. PMID 7680528 DOI: 10.1097/00000441-199303000-00010 |
0.474 |
|
| 1993 |
Krywicki RF, Figueroa JA, Jackson JG, Kozelsky TW, Shimasaki S, Von Hoff DD, Yee D. Regulation of insulin-like growth factor binding proteins in ovarian cancer cells by oestrogen. European Journal of Cancer (Oxford, England : 1990). 29: 2015-9. PMID 7506561 DOI: 10.1016/0959-8049(93)90464-Q |
0.476 |
|
| 1992 |
Yee D. Can the insulin-like growth factors regulate breast cancer growth? Breast Cancer Research and Treatment. 22: 3-5. PMID 1421421 DOI: 10.1007/Bf01833328 |
0.529 |
|
| 1992 |
Figueroa JA, Yee D. The insulin-like growth factor binding proteins (IGFBPs) in human breast cancer Breast Cancer Research and Treatment. 22: 81-90. PMID 1384805 DOI: 10.1007/Bf01833336 |
0.607 |
|
| 1992 |
Krywicki RF, Yee D. The insulin-like growth factor family of ligands, receptors, and binding proteins. Breast Cancer Research and Treatment. 22: 7-19. PMID 1384804 DOI: 10.1007/Bf01833329 |
0.486 |
|
| 1992 |
McGuire WL, Jackson JG, Figueroa JA, Shimasaki S, Powell DR, Yee D. Regulation of insulin-like growth factor-binding protein (IGFBP) expression by breast cancer cells: use of IGFBP-1 as an inhibitor of insulin-like growth factor action. Journal of the National Cancer Institute. 84: 1336-41. PMID 1379645 DOI: 10.1093/Jnci/84.17.1336 |
0.578 |
|
| 1992 |
Martin DM, Yee D, Feldman EL. Gene expression of the insulin-like growth factors and their receptors in cultured human retinal pigment epithelial cells Molecular Brain Research. 12: 181-186. PMID 1372066 DOI: 10.1016/0169-328X(92)90082-M |
0.453 |
|
| 1992 |
Martin DM, Yee D, Carlson RO, Feldman EL. Gene expression of the insulin-like growth factors and their receptors in human neuroblastoma cell lines Molecular Brain Research. 15: 241-246. PMID 1331680 DOI: 10.1016/0169-328X(92)90114-Q |
0.459 |
|
| 1991 |
Yee D, Favoni RE, Lippman ME, Powell DR. Identification of insulin-like growth factor binding proteins in breast cancer cells Breast Cancer Research and Treatment. 18: 3-10. PMID 1713084 DOI: 10.1007/Bf01975437 |
0.555 |
|
| 1991 |
Yee D, Rosen N, Favoni RE, Cullen KJ. The insulin-like growth factors, their receptors, and their binding proteins in human breast cancer Cancer Treatment and Research. 53: 93-106. PMID 1672092 DOI: 10.1007/978-1-4615-3940-7_5 |
0.614 |
|
| 1991 |
Cullen KJ, Yee D, Rosen N. Insulinlike growth factors in human malignancy Cancer Investigation. 9: 443-454. PMID 1653087 DOI: 10.3109/07357909109084643 |
0.328 |
|
| 1991 |
Rosen N, Yee D, Lippman ME, Paik S, Cullen KJ. Insulin-like growth factors in human breast cancer Breast Cancer Research and Treatment. 18. PMID 1651793 DOI: 10.1007/Bf02633529 |
0.615 |
|
| 1990 |
Yee D, Favoni RE, Lebovic GS, Lombana F, Powell DR, Reynolds CP, Rosen N. Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation: A potential autocrine growth factor Journal of Clinical Investigation. 86: 1806-1814. PMID 2174908 DOI: 10.1172/Jci114910 |
0.444 |
|
| 1990 |
Tobin G, Yee D, Brünner N, Rotwein P. A novel human insulin-like growth factor I messenger RNA is expressed in normal and tumor cells. Molecular Endocrinology. 4: 1914-1920. PMID 2082190 DOI: 10.1210/Mend-4-12-1914 |
0.421 |
|
| 1989 |
Yee D, Paik S, Lebovic GS, Marcus RR, Favoni RE, Cullen KJ, Lippman ME, Rosen N. Analysis of insulin-like growth factor I gene expression in malignancy: Evidence for a paracrine role in human breast cancer Molecular Endocrinology. 3: 509-517. PMID 2747657 DOI: 10.1210/Mend-3-3-509 |
0.559 |
|
| 1989 |
Cullen KJ, Yee D, Bates SE, Brunner N, Clarke R, Dickson RE, Huff KK, Paik S, Kosen N, Valverius E, Zugmaier G, Lippman ME. Regulation of human breast cancer by secreted growth factors Acta Oncologica. 28: 835-839. PMID 2692646 DOI: 10.3109/02841868909092318 |
0.524 |
|
| 1989 |
Yee D, Favoni RE, Lupu R, Cullen KJ, Lebovic GS, Huff KK, Lee PDK, Lee YL, Powell DR, Dickson RB, Rosen N, Lippman ME. The insulin-like growth factor binding protein BP-25 is expressed by human breast cancer cells Biochemical and Biophysical Research Communications. 158: 38-44. PMID 2463838 DOI: 10.1016/S0006-291X(89)80173-1 |
0.52 |
|
| 1989 |
Yee D, Lippman ME. Growth Regulation of Breast Cancer Progress in Clinical and Biological Research. 320: 315-342. DOI: 10.1007/978-3-642-73718-3_17 |
0.52 |
|
| Show low-probability matches. |